Updates

John Rother on Rising Price of Opioid Overdose Treatment

May 11, 2016

"Drug companies seem to be taking advantage of increased demand for Naloxone during this public health crisis by raising the price of a literally lifesaving medication," said John Rother, executive director of the Campaign for Sustainable Rx Pricing. Read More

S&P Report Finds Rx Prices Driving Increased Health Care Costs

May 10, 2016

"Annual prescription price hikes are driving the overall increase in health care costs and making health care less affordable for Americans. Today's S&P report confirms what we've been saying — these increases in drug cost are unsustainable — and solutions to promote transparency, increase competition, and focus on value must be advanced," said John Rother, executive director of the Campaign for Sustainable Rx Pricing (CSRxP). Read More

Real People. Unconscionable Numbers.

May 5, 2016

Troubling numbers from the Centers for Disease Control and Prevention (CDC) this week show nearly 3.5 million Americans are currently living with hepatitis C – many of which are unaware of their infection. Luckily, this chronic illness is treatable, but at a staggering cost. Read More

CSRxP Introduces Proposals for Change

Apr 27, 2016

The Campaign for Sustainable Rx Pricing (CSRxP) kicked off the week with the introduction of its new policy platform aimed to curb skyrocketing prescription drug prices through increased transparency and competition which results in value. CSRxP’s solutions come at a critical time in the conversation about drug pricing, as this bipartisan issue garners unprecedented attention among policymakers, voters, and presidential candidates. Read More

Quick Facts About Rising Prescription Drug Costs

Apr 25, 2016

Drug prices in the United States are too high and continue to skyrocket. The unsustainable cost of prescription drugs not only puts pressure on the health care system but increasingly; patients, employers, and providers are paying prices that are too high. Read More

Proposals for Change: Transparency, Competition and Value

Apr 25, 2016

Drug prices in the United States are too high and sharply rising prescription drug prices threaten the affordability of health care and the vitality of our entire economy. CSRxP has developed market-based reforms that restore a functioning market by increasing transparency, promoting competition and innovation, and that result in value. Read More

CSRxP to Unveil Market-Based Solutions to Address Soaring Drug Prices

Apr 20, 2016

The Campaign for Sustainable Rx Pricing (CSRxP) will release market-based policy solutions to curb rising drug prices at a discussion at the Newseum in Washington, DC on Monday, April 25th at 10:00 a.m. Read More

Walmart Joins Campaign for Sustainable Rx Pricing

Apr 19, 2016

“It’s important to Walmart to help find solutions to health care costs that continue to rise for individuals and the companies that insure them. With more than 1.1 million associates and family members on Walmart’s health care plans and millions of customers that visit pharmacies in our stores and clubs each week, we understand the importance of quality, affordable health care," said Sally Welborn, senior vice president of global benefits at Walmart. Read More

John Rother Statement on IMS Health Report

Apr 14, 2016

“Excessive price hikes on prescription drugs drive up spending year after year with no end in sight. Drug makers' annual habit of demanding a blank check, without reference to any change in value from patients and taxpayers, makes it harder for American families to make ends meet. Ultimately, these price increases make health care more expensive for all of us, even those who don’t use prescription drugs. It’s outrageous.” Read More

Nurse Anesthetists Sign on to Campaign for Sustainable Rx Pricing

Apr 14, 2016

Today the National Coalition on Health Care Action Fund announced that the American Association of Nurse Anesthetists (AANA) has joined the coalition’s Campaign for Sustainable Rx Pricing which works to find market-based solutions to rising prescription drug prices. Read More

How Do We Deal With Rising Drug Costs?

Apr 12, 2016

"There is no silver bullet here. We need to balance affordability, access and innovation whether or not Medicare is directly involved in price negotiations. We can only strike that balance when the market has transparency and competition, and purchasers can pay for value." Read More

John Rother Statement on Reuters Analysis of Prescription Drug Price Increases

Apr 4, 2016

“This is further evidence that skyrocketing drug prices are more widespread than a few bad actors. When major drug companies hike prices on common prescription drugs, Americans suffer. Families are forced to decide between paying for prescriptions or paying bills, and that’s wrong.” Read More